Opioids bind to mu, kappa, and delta receptors throughout the brain and spinal cord, mimicking the body's own pain-suppressing chemicals to blunt pain signals. They work powerfully — and also activate the brain's dopamine reward system, which drives tolerance, physical dependence, and addiction. Fentanyl and oxycodone are Schedule II; tramadol is Schedule IV. Overdose causes life-threatening respiratory depression and is reversible with naloxone (Narcan). If you suspect an overdose, call 911 immediately and give naloxone if available.
How Opioids Work: A Complete Guide to Opioid Pain Medications
Opioids are among the most effective pain-relieving agents ever discovered — and among the most misunderstood. They relieve suffering for cancer patients, surgical patients, and people with serious acute injuries. They also carry a real risk of dependence, addiction, and overdose that has contributed to one of the most severe drug crises in American history.
Understanding how opioids actually work — at the receptor level, in the reward circuitry, and in the body's physiological adaptation — helps patients take them more safely, recognize warning signs earlier, and have better-informed conversations with their prescribers. It also helps family members and bystanders understand what an overdose looks like and what to do about it. This article covers all of it, plainly.
What Are Opioids? Receptors, Endorphins, and the Pain Gate
The human body has its own built-in opioid system. Three families of naturally occurring molecules — endorphins, enkephalins, and dynorphins — are produced in the brain and spinal cord and bind to opioid receptors to modulate pain, mood, and stress responses. These endogenous opioids are why vigorous exercise can produce a euphoric "runner's high," why the body's pain perception blunts in the immediate aftermath of trauma, and why social connection feels physically rewarding.
Opioid drugs work by binding to the same receptors these natural molecules use — but far more powerfully and persistently. Three main receptor types have been identified:
- Mu (μ) receptors — the primary target for pain relief and also the receptor most responsible for euphoria, sedation, respiratory depression, constipation, and physical dependence. Nearly all clinically used opioid analgesics exert their main effects here.
- Kappa (κ) receptors — involved in analgesia and sedation, but activation also produces dysphoria (a deeply unpleasant feeling) rather than euphoria, which limits their abuse potential.
- Delta (δ) receptors — contribute to mood modulation, anxiety reduction, and some analgesic effects; also implicated in tolerance development.
When an opioid binds the mu receptor, it suppresses the release of neurotransmitters involved in pain signal transmission — particularly substance P and glutamate — at synapses in the dorsal horn of the spinal cord. It also activates descending pain-inhibition pathways from the brainstem (the periaqueductal gray region) that actively suppress incoming pain signals. The result is a two-pronged block: the pain signal is intercepted at the spine before it reaches the brain, and the brain's own pain-suppression system is amplified.
Mu receptor activation in the brainstem also reduces the activity of the respiratory control center — this is what makes opioid overdose lethal. Breathing slows, becomes shallow, and can stop entirely. This is not a side effect of therapeutic opioid use at appropriate levels; it is the dose-dependent consequence of excessive mu receptor activation.
Types of Opioids: Natural, Semi-Synthetic, and Fully Synthetic
Opioids are classified by their origin: whether they come directly from the opium poppy, are chemically modified from plant-derived compounds, or are synthesized entirely in a laboratory.
Natural Opioids (Opiates)
Extracted directly from the resin of Papaver somniferum, the opium poppy. Morphine is the primary active alkaloid and remains the reference standard against which other opioids' potency is measured. Codeine is a weaker natural opiate, notable for its use in cough suppression and mild-to-moderate pain relief; it is a prodrug that the body converts to morphine via the CYP2D6 enzyme — people with certain genetic variants either convert too little (poor analgesic effect) or too much (dangerous toxicity from normal doses).
Semi-Synthetic Opioids
Chemically derived from natural opiates through structural modification. This class includes some of the most widely prescribed and most widely misused opioids:
- Oxycodone (OxyContin, Percocet when combined with acetaminophen) — derived from thebaine, another poppy alkaloid. Available in immediate-release and extended-release formulations.
- Hydrocodone (Vicodin when combined with acetaminophen, Zohydro ER alone) — widely prescribed for acute pain.
- Hydromorphone (Dilaudid) — significantly more potent than morphine; used for severe pain.
- Heroin (diacetylmorphine) — a semi-synthetic opioid derived from morphine, with no approved medical use in the United States. It crosses the blood-brain barrier faster than morphine, which intensifies its euphoric effect and abuse liability.
- Buprenorphine (Suboxone, Subutex, Belbuca) — a partial agonist at the mu receptor and antagonist at the kappa receptor; used in opioid use disorder treatment and for chronic pain.
Fully Synthetic Opioids
Synthesized entirely in the laboratory with no plant-derived starting material, though they bind the same receptors as natural opiates:
- Fentanyl (Duragesic patch, Actiq lozenge, Sublimaze injection) — approximately 100 times more potent than morphine by weight; widely used in anesthesia and for cancer-related pain. Illicitly manufactured fentanyl has become the dominant driver of overdose deaths since the mid-2010s.
- Methadone — a long-acting opioid with a complex pharmacological profile; used both for chronic pain and as a treatment for opioid use disorder through federally regulated opioid treatment programs.
- Tramadol (see tramadol drug page) — a weaker opioid agonist that also inhibits reuptake of serotonin and norepinephrine; classified as Schedule IV. Commonly regarded as lower-risk, though overdose, serotonin syndrome, and dependence remain real concerns.
| Drug | Type | Schedule | Available Strengths (examples) | Notes |
|---|---|---|---|---|
| Morphine | Natural | Schedule II | 15mg, 30mg IR; 15mg–200mg ER | Reference standard for opioid potency comparisons |
| Oxycodone (OxyContin) | Semi-synthetic | Schedule II | 5mg, 10mg, 15mg, 20mg, 30mg IR; 10mg–80mg ER | High abuse liability; ER formulation tamper-resistant |
| Hydrocodone (Vicodin) | Semi-synthetic | Schedule II | 2.5mg, 5mg, 7.5mg, 10mg | Most commonly prescribed opioid in U.S. |
| Fentanyl (Duragesic) | Synthetic | Schedule II | 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr patches | ~100× more potent than morphine; patches for chronic pain |
| Buprenorphine (Suboxone) | Semi-synthetic | Schedule III | 2mg, 8mg sublingual; various film strengths | Partial agonist; ceiling effect limits overdose risk |
| Tramadol | Synthetic | Schedule IV | 50mg, 100mg IR; 100mg–300mg ER | Also inhibits serotonin/norepinephrine reuptake |
| Methadone | Synthetic | Schedule II | 5mg, 10mg tablets; liquid formulations | Long, unpredictable half-life; complex cardiac interactions |
Medical Uses of Opioids
Opioids have legitimate and important medical applications. Understanding the appropriate use cases helps contextualize the risk-benefit calculus that prescribers navigate.
Acute Pain
Opioids are appropriate and effective for severe acute pain — post-surgical pain, traumatic injury, kidney stones, sickle cell crisis, and other conditions where pain is intense and expected to resolve within days to weeks. Short-course opioid prescribing for acute pain (typically limited to a few days for most conditions) carries substantially lower risk than long-term prescribing. Guidelines increasingly recommend limiting opioid prescriptions for acute pain to the shortest effective duration.
Chronic Non-Cancer Pain
The role of opioids in long-term management of chronic non-cancer pain has become deeply contested. Evidence of sustained benefit is weak, risks of dependence, opioid-induced hyperalgesia, and adverse events accumulate over time, and the 2022 CDC Clinical Practice Guideline for Prescribing Opioids substantially revised guidance downward. Long-term opioid therapy may still be appropriate for carefully selected patients who have tried and not responded to other approaches, but this is a complex clinical decision requiring ongoing reassessment.
Cancer Pain and Palliative Care
Opioids are a cornerstone of cancer pain management and palliative care. For patients with moderate-to-severe cancer pain, or those in hospice or end-of-life care, adequate opioid analgesia is an ethical priority. Concerns about dependence are less clinically relevant in this context, and undertreated pain in cancer patients is a documented and serious harm.
Cough Suppression
Codeine and, less commonly, hydrocodone are used as antitussives (cough suppressants). Codeine-containing cough syrups (some in Schedule V) were historically very widely prescribed; their use has narrowed considerably given concerns about misuse and codeine's variable metabolism. Dextromethorphan, a non-opioid antitussive, is preferred in most guidelines for ordinary cough.
Opioid Use Disorder Treatment
Methadone and buprenorphine (Suboxone, which combines buprenorphine with naloxone) are FDA-approved medications for opioid use disorder (OUD). They reduce cravings, block the euphoric effect of illicit opioids, and dramatically reduce overdose mortality. Methadone for OUD must be dispensed through federally regulated opioid treatment programs (OTPs); buprenorphine can be prescribed by qualified clinicians in office-based settings. Both are evidence-based, effective, and underutilized relative to need. See also: how long Suboxone stays in your system.
How Opioids Cause Dependence and Addiction
Dependence and addiction are related but distinct phenomena, and conflating them causes real harm — both by stigmatizing patients who are physically dependent on appropriately prescribed opioids, and by understating the risks of the brain changes that underlie addiction.
Tolerance
With repeated opioid use, the brain adapts. Neurons with mu receptors begin to internalize those receptors (reducing their number on the cell surface) and to downregulate their signaling pathways. The same amount of drug produces less effect. This is tolerance — a pharmacological inevitability with regular opioid use, not a moral failing. Patients on long-term opioid therapy regularly need increased amounts to maintain the same level of pain control. Tolerance also develops to the euphoric effects faster than to the analgesic effects, which can contribute to dose escalation patterns in people misusing opioids.
Physical Dependence
Physical dependence is a physiological state in which the body has adapted to the presence of the drug; abrupt discontinuation causes withdrawal. Opioid withdrawal is intensely uncomfortable — including muscle cramps, sweating, diarrhea, insomnia, anxiety, and severe restlessness — but is rarely life-threatening in otherwise healthy adults (unlike alcohol or benzodiazepine withdrawal). Physical dependence can develop in any patient taking opioids regularly, including patients taking them exactly as prescribed. It does not, by itself, constitute addiction.
Addiction (Opioid Use Disorder)
Addiction — formally diagnosed as opioid use disorder — involves compulsive drug-seeking and use despite harmful consequences, loss of control over use, and continued use despite negative impact on health, relationships, and functioning. Its biological substrate is neuroadaptation in the brain's dopamine reward system.
Opioids trigger a massive release of dopamine in the nucleus accumbens — the brain's primary reward hub — far exceeding what natural rewards produce. With repeated use, the brain compensates: baseline dopamine levels drop, the number of dopamine receptors decreases, and nothing feels as rewarding as the drug once did. This is the hedonic set-point shift of addiction. The brain has been recalibrated to need the drug not just to feel good, but to feel normal.
Not everyone who takes opioids develops addiction. Risk factors include genetics (family history of addiction), prior history of substance use disorder, co-occurring mental health conditions (particularly depression, anxiety, PTSD), early-onset use (adolescent brain is more vulnerable to neuroadaptation), and social environment. Risk is real but not universal; most patients prescribed opioids for acute pain do not develop OUD.
Opioid Overdose: Recognition, Response, and Naloxone
Opioid overdose kills by suppressing the brain's drive to breathe. The respiratory center in the brainstem — which automatically triggers each breath — is progressively shut down as opioid levels rise. Death occurs from hypoxia: the body is deprived of oxygen as breathing slows and stops.
Signs of Opioid Overdose
Recognizing an overdose is the first and most critical step. The classic triad:
- Pinpoint pupils — pupils that do not dilate even in dim light; a specific sign of opioid toxicity
- Slow, shallow, or stopped breathing — fewer than one breath every 5 seconds, or no breathing at all; the person may be making gurgling or snoring sounds ("death rattle")
- Unconsciousness or unresponsiveness — cannot be woken up with sternal rub or loud voice; may appear to be "sleeping"
Skin may be pale, blue-tinged (cyanotic) around the lips or fingertips, or cold and clammy. The person may be limp and unresponsive.
⚠ If you suspect an opioid overdose: call 911 immediately. Give naloxone (Narcan) if available. Perform rescue breathing. Place the person in the recovery position if breathing. Stay with them until emergency services arrive — naloxone wears off before most opioids do. Most states have Good Samaritan laws that provide legal protection for people who call 911 to report an overdose.
Naloxone (Narcan) Reversal
Naloxone is an opioid antagonist that rapidly displaces opioid molecules from mu receptors and blocks them, reversing respiratory depression within minutes. It does not produce euphoria or have abuse potential. Naloxone is available without a prescription at most pharmacies in the United States as a nasal spray (Narcan, Kloxxado) and injectable formulation.
Critical limitation: naloxone's effects last approximately 30–90 minutes, which is shorter than the duration of most opioids — including fentanyl formulations. A person may wake up after naloxone, then slip back into overdose as the naloxone wears off and the opioid resumes activity. A second or third dose of naloxone may be needed. This is why calling 911 is non-negotiable even when naloxone is on hand and appears to work.
Naloxone will precipitate immediate, severe withdrawal in someone who is physically dependent on opioids. This is extremely uncomfortable but not dangerous. It does not harm someone who has not taken opioids.
For more on fentanyl's duration and detection, see: How Long Does Fentanyl Stay in Your System?
DEA Scheduling of Opioids
The DEA schedules controlled substances based on their accepted medical use and their potential for abuse and dependence. For opioids, scheduling has direct practical implications: which prescriptions require paper triplicate forms (in some states), how many refills are permitted, whether a phone call or fax suffices for prescribing, and what record-keeping is required. See the full controlled substances guide.
Scheduling does not directly indicate a drug's potency or danger — it reflects regulatory judgment about medical utility and abuse potential. Fentanyl is more potent than tramadol, but both can cause overdose and both cause dependence. Tramadol, though Schedule IV, carries real risks that its scheduling can understate.
The Opioid Crisis: How It Started and Where It Stands
The United States has experienced overlapping waves of opioid crisis since the late 1990s. Understanding its arc helps contextualize the current landscape of prescribing restrictions, harm reduction, and overdose patterns.
Wave 1: The Prescription Opioid Surge
In the late 1990s and 2000s, pharmaceutical manufacturers — most infamously Purdue Pharma, maker of OxyContin — aggressively marketed extended-release opioids as safe and non-addictive for chronic non-cancer pain. Misleading claims about addiction risk, aggressive sales tactics targeting primary care physicians, and overly permissive prescribing guidelines created an environment in which opioid prescribing rates climbed dramatically. "Pill mills" — clinics that prescribed opioids with little or no legitimate medical justification — proliferated in some states, particularly Florida, Ohio, West Virginia, and Kentucky. Prescription opioid dispensing in the U.S. peaked around 2010–2012 at roughly 255 million prescriptions annually.
Wave 2: The Heroin Transition
As prescribing crackdowns tightened access to prescription opioids in the early 2010s, many people who had developed opioid use disorder transitioned to heroin — cheaper, more available, and delivering a comparable effect. Overdose deaths from heroin accelerated from roughly 2010 through 2016.
Wave 3: Illicitly Manufactured Fentanyl
The most lethal phase of the crisis began as illicitly manufactured fentanyl began contaminating — and then essentially replacing — the heroin supply from roughly 2016 onward. Fentanyl's extreme potency per weight makes it highly profitable to produce and traffic, but it makes accurate dosing by users essentially impossible. A counterfeit pill or a bag of powder that appears identical to another can carry a lethal amount in one portion and a sub-lethal amount in another. Fentanyl is now detected in the illicit supply of stimulants (cocaine, methamphetamine) as well as opioids, meaning people who do not intend to use an opioid may nonetheless be exposed. Overdose deaths exceeded 80,000 per year in recent years, with synthetic opioids involved in the large majority.
Current Harm Reduction Approaches
Public health response has expanded beyond law enforcement and prescribing restriction toward harm reduction — strategies that reduce the health consequences of drug use without requiring abstinence as a prerequisite for help:
- Naloxone distribution — widespread availability of naloxone at pharmacies, community organizations, and harm reduction programs has saved countless lives
- Fentanyl test strips — allow people to test substances for fentanyl contamination before use; increasingly legally available after many states removed them from paraphernalia laws
- Medications for OUD (MOUD) — expanding access to buprenorphine and methadone in jails, emergency departments, primary care offices, and telehealth settings
- Syringe service programs (SSPs) — reduce HIV and hepatitis C transmission and serve as entry points into treatment
Frequently Asked Questions
What is the strongest opioid?
Fentanyl is among the most potent opioids used medically, estimated to be roughly 100 times more potent than morphine by weight. Sufentanil, used in anesthesia, is more potent still. Carfentanil, a veterinary analog of fentanyl used to sedate large animals, is far more potent with no approved human use. Potency comparisons are often misunderstood: a more potent opioid is not simply a "stronger" pain reliever — it means a smaller amount achieves the same effect, and also that the margin between a therapeutic amount and a dangerous one is much narrower. Illicitly manufactured fentanyl dominates the overdose crisis today precisely because its extreme potency makes contamination of any street drug supply extremely dangerous.
What is the difference between opiates and opioids?
Technically, "opiate" refers specifically to compounds derived directly from the opium poppy — morphine and codeine are the classic opiates. "Opioid" is the broader umbrella term that includes natural opiates, semi-synthetic derivatives (like oxycodone and hydrocodone, chemically modified from plant-derived compounds), and fully synthetic compounds (like fentanyl and methadone) that bind the same receptors but are made entirely in the laboratory. In modern clinical and public health usage, "opioid" is used for the entire class. The older "opiate" distinction is largely historical and the terms are often used interchangeably in everyday speech.
How long do opioids stay in your system?
Detection windows vary by drug, formulation, frequency of use, individual metabolism, and the type of test used. As a general guide: short-acting opioids like oxycodone and hydrocodone are typically detectable in urine for 2–4 days after occasional use; morphine for 2–3 days. Methadone, a long-acting opioid, may be detectable in urine for up to 2 weeks. Buprenorphine can be detected for several days to over a week. Fentanyl is typically detectable in urine for 24–72 hours, though its metabolite norfentanyl may remain longer. Hair follicle testing can detect most opioids for up to 90 days. Detection windows extend with chronic heavy use. See also: how long Suboxone stays in your system and how long fentanyl stays in your system.
What is naloxone and how does it work?
Naloxone (brand names Narcan, Kloxxado) is an opioid antagonist — a molecule that binds the mu receptor with very high affinity but does not activate it. When given during an overdose, it rapidly displaces opioid molecules from the receptor and blocks further binding, reversing respiratory depression within minutes. Naloxone has a critical limitation: its effects last roughly 30–90 minutes, shorter than most opioids. A person who appears to recover may lapse back into overdose as naloxone wears off. A second or third dose may be needed. Always call 911 even after naloxone appears to work. Naloxone is available without a prescription at most U.S. pharmacies.
What is opioid-induced hyperalgesia?
Opioid-induced hyperalgesia (OIH) is a paradoxical condition in which prolonged opioid use increases, rather than decreases, a person's sensitivity to pain. Instead of adequate pain control, patients may notice that their pain worsens or spreads beyond its original location, and that stimuli that were not previously painful become painful. The mechanism involves neuroadaptation: chronic opioid exposure sensitizes pain pathways through changes in NMDA receptor signaling, central sensitization, and descending pain facilitation circuits. OIH is distinct from simple tolerance — tolerance means the drug works less; hyperalgesia means pain actually increases as a direct effect of the drug. It complicates long-term opioid prescribing for chronic non-cancer pain and is one factor driving guidelines toward greater caution with long-term opioid therapy.
Identify a pill, check opioid interactions, or look up a controlled substance by name or imprint.
Search PillID